US FDA accepts Valeant and GSK's filing for anti-epileptic retigabine
This article was originally published in Scrip
Executive Summary
The US FDA has accepted Valeant Pharmaceuticals and GlaxoSmithKline's NDA for their anti-epileptic candidate retigabine as an adjunctive therapy for adult epilepsy patients with partial-onset seizures.